Anti-C1q Fc-muTP-L309C is a potent modulator of classic component pathway activation

Aug. 30, 2022

Researchers from CSL Behring LLC have investigated the inhibitory properties of an rFc hexamer, named Fc-muTP-L309C, as a modulator of the classic component pathway activation.

BioWorld Science Conferences Immunotherapy Immune

Today's news in brief

BioWorld

BioWorld briefs for Dec. 8, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 8, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...